Plain-English translation of NCT05593458 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new way to deliver chemotherapy for advanced stomach cancer. Instead of giving chemotherapy through a vein in your arm like usual, researchers are testing whether injecting oxaliplatin directly into the artery that feeds the stomach tumor—combined with an oral pill called S-1 and an immune-boosting drug—might work better. You would receive this treatment before surgery to shrink the tumor, have your stomach removed, then receive more chemotherapy afterward.
Standard chemotherapy for advanced stomach cancer works reasonably well, but doctors are looking for ways to help more patients survive longer and have better outcomes after surgery. By delivering the medication directly to the tumor's blood supply, researchers hope the treatment will be more effective while still being safe.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. Both groups follow the same basic schedule: three cycles of chemotherapy plus immune-boosting medication given before surgery (about 2–3 months), then surgery to remove your stomach, then three more cycles of chemotherapy plus immune-boosting medication after surgery (about 2–3 months). The main difference is how the chemotherapy is delivered—either through a special catheter into the artery feeding your tumor, or through a standard IV. After that, you will take an oral medication for up to one year. Researchers will monitor your health with blood tests, imaging scans, and follow-up visits to compare how well each approach works.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China